BRIEF—Eisai finally secures reimbursement for Fycompa in Germany

Tokyo’s Eisai says Fycompa (perampanel) will be regularly available in Germany from next month, after the firm agreed a price for the drug with Germany’s National Association of Statutory Health Insurance Funds.

The firm withdrew the drug from the market in 2013 after authorities found no additional benefit or innovative value, a prerequisite for insurance reimbursement pricing negotiations.

New negotiations became possible earlier this year due to a change in the law, which led to the current agreement.

The drug was approved in the EU in July 2012, as an adjunctive treatment for certain adult and juvenile epilepsy patients.